logo-loader
viewANGLE PLC

ANGLE’s Parsortix system could help “significantly improve” diagnosis and treatment of lung cancer

New research points to lung cancer being a "major opportunity" for the company to pursue once its current studies on breast cancer and ovarian cancer have concluded

ANGLE PLC - ANGLE’s Parsortix system could help “significantly improve” diagnosis and treatment of lung cancer
The technology is still being honed, but ANGLE is “encouraged” by the researchers’ work

ANGLE PLC’s (LON:AGL) Parsortix liquid biopsy has shown it has the potential to help doctors diagnose lung cancer faster and more accurately.

Parsortix is a simple blood test that detects and captures circulating tumour cells (CTCs), which provide the tell-tale signs of cancer.

Researchers at the Medical University of Vienna looked for neuroendocrine markers on these CTCs, which were found to correlate with patients’ overall survival: the more markers, the more aggressive the cancer.

READ: ANGLE still 'on track' for FDA submission of Parsortix cancer-detecting system this year

Not only could this speed up a patient’s initial diagnosis, but further liquid biopsies could also help to guide treatment plans as the cancer evolves.

RNA analysis of the CTCs could also help determine which drugs are likely to be most effective for a particular patient.

Professor Robert Zeillinger, head of the Molecular Oncology Group at the university, said this new approach has “the potential to significantly improve the way that lung cancer is diagnosed and treated”.

ANGLE founder and chief executive Andrew Newland added: “Lung cancer is a major opportunity for ANGLE to pursue once we have concluded our current FDA and verification studies in breast cancer and ovarian cancer.

“We are encouraged by the work of Vienna, and others, in this area. There is a clear benefit to lung cancer patients in faster diagnosis, longitudinal monitoring and reducing invasive procedures as well as a strong health economic argument to reduce healthcare costs.”

Quick facts: ANGLE PLC

Price: 75.15 GBX

AIM:AGL
Market: AIM
Market Cap: £129.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: ANGLE aiming for FDA approval of Parsortix in third quarter

ANGLE (LON:AGL) CEO Andrew Newland is confident that his company will receive regulatory clearance for its innovative Parsortix cancer test by the third quarter 2020 following a successful meeting with the US Food and Drug Administration (FDA). Newland explains why that meeting was...

6 hours, 51 minutes ago

2 min read